Developer docs
API playgroundTry for free, no card

Search company profiles

ITM-Radiopharma

Full company profile

uuid002yhuy

Namestring
ITM-Radiopharma
Legal namestring
ITM Isotope Technologies Munich SE
Company typeenum
Private
Founded yearint
2004
Descriptiontext

ITM Isotope Technologies Munich SE (ITM Radiopharma) is a privately held radiopharmaceutical biotech company founded in 2004 as a spin-off from the Technical University of Munich, headquartered in Garching near Munich, Germany, with a U.S. regional headquarters in Princeton, New Jersey. The company develops and supplies targeted radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors, combining proprietary medical radioisotopes—notably non-carrier-added (n.c.a.) Lutetium-177 and Actinium-225—with targeting molecules such as edotreotide, PSMA ligands, and somatostatin receptor antagonists to deliver precision radiation to cancer cells. Its clinical pipeline spans ITM-11 (n.c.a. 177Lu-edotreotide) for gastroenteropancreatic neuroendocrine tumors, which met its Phase 3 COMPETE primary endpoint with a statistically significant improvement in progression-free survival (23.9 vs 14.1 months vs everolimus, p=0.022), ITM-31 for glioblastoma, ITM-22 for prostate cancer, and an emerging Terbium-161 program (ITM-63, ITM-23). Manufacturing is anchored by the IAZ Production Facility co-located with the FRM II research reactor in Garching and the NOVA Production Facility in Neufahrn, with a global supply network reinforced by a long-standing technology transfer agreement with NTP Radioisotopes in South Africa.

The company operates a B2B enterprise sales motion with three revenue streams: radioisotope supply (Lutetium-177 n.c.a. and Actinium-225) sold to hospitals, pharmaceutical companies, and radiopharmacies; investigational radiopharmaceutical supply through clinical trials and expanded access programs targeting oncology centers and nuclear medicine departments; and radiolabeling technical services and equipment provision. Specialized sales channels—RadioisotopeOperations, RadiopharmaOperations, and TechnicalServices—route customer inquiries to the appropriate operational team. Marketing is driven by scientific engagement through major oncology and nuclear medicine conferences (ASCO, SNMMI, EANM, ENETS, ESMO, NANETS), peer-reviewed publications, and a registered healthcare-professional portal, with corporate communications amplified via LinkedIn and YouTube. Capital structure is anchored by a USD 262.5 million non-dilutive debt facility transferred from Blue Owl Managed Funds to Perceptive Advisors in June 2026, supporting pipeline advancement and commercial-scale manufacturing build-out ahead of ITM-11's anticipated regulatory and commercial milestones.

Short descriptiontext

ITM Isotope Technologies Munich SE is a privately held radiopharmaceutical biotech company that develops and supplies targeted radiopharmaceutical therapeutics and diagnostics, combining proprietary Lutetium-177 and Actinium-225 radioisotopes with targeting molecules for hard-to-treat tumors in oncology and nuclear medicine.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersGarching Bei München, Germany
HQ citystring
Garching Bei München
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
radiopharmaceutical therapeutics, medical radioisotope production, precision oncology pipeline, targeted radionuclide therapy, Lutetium-177 supply
Industry5 codes
PRIMARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAD
Radioisotope Production (Reactor/Cyclotron/Gamma)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAF
Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAH
Radionuclide Supply Chain & Logistics (Shielding/Transport/Distribution)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAC
Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
NAICS code3 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
  • Services-Commercial Physical & Biological Research8731
Product category
Radiopharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Radioisotope Supply
TypeHardware Sales
Description

ITM supplies medical radioisotopes (Lutetium-177 n.c.a., Actinium-225) to hospitals, pharmaceutical companies, and radiopharmacies globally. This includes both research-grade and GMP-quality isotopes for diagnostic and therapeutic applications.

itm-radiopharma.com
2Radiopharmaceutical Products
TypeLicensing Royalties
Description

Proprietary radiopharmaceutical therapeutics and diagnostics in clinical development, targeting neuroendocrine tumors, prostate cancer, and glioblastoma. The company operates clinical trial programs and expanded access programs for investigational products.

itm-radiopharma.com
3Technical Services and Equipment
TypeProfessional Services
Description

Radiolabeling services and equipment provision for hospitals and radiopharmacies preparing radiopharmaceuticals for clinical use.

itm-radiopharma.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Supply Chain, Infrastructure, Personnel, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

ITM-Radiopharma develops and manufactures targeted radiopharmaceutical therapeutics and diagnostics for precision oncology, combining proprietary radioisotopes (non-carrier-added Lutetium-177 and Actinium-225) with targeting molecules to treat hard-to-treat tumors such as neuroendocrine tumors, prostate cancer, and glioblastoma. The company operates a vertically integrated model spanning radioisotope production at the FRM II research reactor, GMP-certified radiopharmaceutical manufacturing, and global clinical development, supplying both investigational drug products and medical radioisotopes to hospitals, nuclear medicine departments, and clinical trial sites.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • ITM-11 demonstrated clinically and statistically significant improvement in progression-free survival (23.9 vs 14.1 months) compared to everolimus in GEP-NET patients (p=0.022)
+3 more records
Product overview1 text field

ITM Isotope Technologies Munich SE is a leading radiopharmaceutical biotech company that develops a new generation of radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors. The company's offering comprises a broad precision oncology pipeline combining high-quality radioisotopes (Lutetium-177, Actinium-225) with targeting molecules. Key therapeutic candidates include ITM-11 (¹⁷⁷Lu-edotreotide) for neuroendocrine tumors which completed Phase 3 COMPETE trial, ITM-31 for glioblastoma, and ITM-22 for prostate cancer. ITM operates from manufacturing facilities in Germany (Garching, Neufahrn) with a U.S. headquarters in Princeton, NJ, leveraging two decades of radiopharma expertise and established global supply networks.

Product and service10 records
1ITM-11 (n.c.a. 177Lu-edotreotide)
CategoryTherapeutic Radiopharmaceutical
Description

Proprietary targeted radiotherapeutic investigational agent combining non-carrier-added Lutetium-177 with edotreotide for treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs); supplied to clinical trial sites and Expanded Access Programs through Medical Affairs.

2ITM-31
CategoryTherapeutic Radiopharmaceutical
Description

Investigational targeted radiotherapeutic candidate for glioblastoma developed as part of ITM's precision oncology pipeline.

3ITM-22 (ITM-24d)
CategoryTherapeutic Radiopharmaceutical
Description

Investigational targeted radiotherapeutic candidate for prostate cancer, part of ITM's precision oncology pipeline.

4ITM-63 (Terbium-161 DOTA-LM3)
CategoryTherapeutic Radiopharmaceutical
Description

Investigational somatostatin receptor antagonist radiolabeled with Terbium-161 for treatment of gastroenteropancreatic neuroendocrine tumors; Phase 0 study ongoing.

5ITM-23 (161Tb-SibuDAB)
CategoryTherapeutic Radiopharmaceutical
Description

Investigational PSMA ligand radiolabeled with Terbium-161 for targeted radionuclide therapy in metastatic prostate cancer; Phase Ia/b study ongoing.

6Lutetium-177 (n.c.a.)
CategoryMedical Radioisotope
Description

Non-carrier-added Lutetium-177 medical radioisotope supplied globally by ITM for use as a key component in radiopharmaceutical therapeutics and diagnostics for precision oncology applications, sold to hospitals, radiopharmacies, and pharmaceutical companies.

7Actinium-225
CategoryMedical Radioisotope
Description

Alpha-emitting medical radioisotope supplied by ITM for targeted radionuclide therapy applications; ITM is developing production capabilities for global supply.

8COMPETE Phase 3 Trial
CategoryPhase 3 Clinical Study
Description

Phase 3 randomized controlled clinical trial (NCT03049189) evaluating 177Lu-edotreotide vs everolimus in patients with inoperable, progressive Grade 1 or Grade 2 gastroenteropancreatic neuroendocrine tumors, which met its primary PFS endpoint.

9COMPOSE Phase 3 Trial
CategoryPhase 3 Clinical Study
Description

Phase 3 clinical study evaluating 177Lu-edotreotide in patients with well-differentiated, aggressive Grade 2 or Grade 3, somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.

10Radiolabeling Services and Equipment
CategoryTechnical Services and Equipment
Description

Radiolabeling services and equipment provision for hospitals and radiopharmacies preparing radiopharmaceuticals for clinical use, delivered through ITM's Technical Services team.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Long-standing collaboration with Technical University of Munich's FRM II research reactor and Klinikum rechts der Isar for radioisotope production and clinical research. Prof. Wolfgang Weber, Director of Nuclear Medicine at TUM, serves as a key opinion leader and collaborator.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Technology transfer agreement concluded in 2012 with NTP Radioisotopes for reliable and sustainable supply of n.c.a. 177Lu from NTP's GMP-certified facility in Pretoria, South Africa. Supports global supply chain reliability.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration with Center for Radiopharmaceutical Sciences ETHZ-PSI for development of novel radiopharmaceuticals including PSMA radioligands and terbium-based therapies. Prof. Roger Schibli and Prof. Cristina Müller serve as key research collaborators.

4University Hospital Basel
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical research collaboration with Dr. Julia Fricke and Prof. Damian Wild for GEP-NET studies including ITM-63 (DOTA-LM3 terbium-161) and other SSTR-targeting programs. Award-winning research partnership recognized with EANT Marie Curie Award 2024.

itm-radiopharma.com
5International Centers for Precision Oncology (ICPO) Foundation
Strategic tierCoreTypeStrategic or Co-development Partner
Description

ITM supported the ICPO Forum for Theranostics in Precision Oncology, hosted at ITM's headquarters campus in Garching/Munich. Collaborative event bringing together key opinion leaders in precision oncology and theranostics.

20-years.itm-radiopharma.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

U.S. radiopharmaceutical-focused company with a portfolio spanning diagnostic imaging agents (e.g., Pylarify PSMA PET) and an emerging radiotherapeutic pipeline (including 177Lu-PSMA assets). Highly comparable in business model as a vertically integrated diagnostic + therapeutic radiopharma specialist.

TypeBroad incumbent
Description

Global pharma major with approved radioligand therapies Lutathera (177Lu-DOTATATE for GEP-NETs) and Pluvicto (177Lu-PSMA-617 for mCRPC), the dominant incumbents in the exact indications ITM-11 is targeting. Most relevant competitive benchmark for commercial trajectory and pricing dynamics.

TypeOthers
Description

Global medical imaging and life sciences company with a sizable radiopharma manufacturing and distribution business (including 68Ga, 177Lu and theranostic offerings post-MPH acquisition). Broad incumbent with comparable manufacturing footprint and customer base.

TypeDirect peer
Description

Subsidiary of Orano developing lead-212-based alpha-emitter targeted radiotherapies for oncology. Comparable as a next-generation radionuclide therapy developer pursuing a parallel non-Lu-177 platform — directly relevant to ITM's Tb-161/Ac-225 strategy.

TypeBroad incumbent
Description

Major pharma with Xofigo (radium-223) in the radiopharmaceutical space and a growing pipeline of targeted radionuclide therapies (e.g., Nubeqa-AlphaMedix combinations). Broad incumbent in oncology with overlapping radioligand interests.

TypeEmerging player
Description

Belgian startup spun out of SCK CEN focused on large-scale Actinium-225 production for alpha-emitting radiopharmaceuticals. Comparable emerging supplier addressing the same next-generation radionuclide bottleneck ITM is targeting with its Ac-225 program.

TypeDirect peer
Description

Commercial-stage radiopharma company developing and commercializing diagnostic and therapeutic radiopharmaceuticals (Illuccix for PSMA imaging, TLX591 177Lu-rosopatamab for prostate cancer). Closely comparable precision-oncology radiopharma peer with overlapping Lu-177 PSMA and imaging agents.

TypeDirect peer
Description

Privately held diagnostic imaging company with a growing radiopharmaceutical franchise (Blue Earth Diagnostics — Axumin, Posluma). Comparable as a global diagnostic radiopharma manufacturer and commercializer, with ambitions extending into therapeutics.

9PharmaLogic
TypeDirect peer
Description

U.S.-based contract manufacturer and radiopharmacy network producing and distributing PET and SPECT agents, including emerging Lu-177 therapeutic capabilities. Comparable vertically integrated radiopharmacy/CDMO model serving overlapping hospital customers.

TypeDirect peer
Description

One of the world's largest radiopharmaceutical manufacturers, supplying diagnostic and therapeutic nuclear medicine products to hospitals globally. Directly comparable as a vertically integrated radiopharma manufacturer with overlapping isotope and finished-dose capabilities.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries6 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ITM-Radiopharma

Radiopharmaceuticalsitm-radiopharma.com

ITM Isotope Technologies Munich SE is a privately held radiopharmaceutical biotech company that develops and supplies targeted radiopharmaceutical therapeutics and diagnostics, combining proprietary Lutetium-177 and Actinium-225 radioisotopes with targeting molecules for hard-to-treat tumors in oncology and nuclear medicine.

What ITM-Radiopharma does

ITM Isotope Technologies Munich SE (ITM Radiopharma) is a privately held radiopharmaceutical biotech company founded in 2004 as a spin-off from the Technical University of Munich, headquartered in Garching near Munich, Germany, with a U.S. regional headquarters in Princeton, New Jersey. The company develops and supplies targeted radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors, combining proprietary medical radioisotopes—notably non-carrier-added (n.c.a.) Lutetium-177 and Actinium-225—with targeting molecules such as edotreotide, PSMA ligands, and somatostatin receptor antagonists to deliver precision radiation to cancer cells. Its clinical pipeline spans ITM-11 (n.c.a. 177Lu-edotreotide) for gastroenteropancreatic neuroendocrine tumors, which met its Phase 3 COMPETE primary endpoint with a statistically significant improvement in progression-free survival (23.9 vs 14.1 months vs everolimus, p=0.022), ITM-31 for glioblastoma, ITM-22 for prostate cancer, and an emerging Terbium-161 program (ITM-63, ITM-23). Manufacturing is anchored by the IAZ Production Facility co-located with the FRM II research reactor in Garching and the NOVA Production Facility in Neufahrn, with a global supply network reinforced by a long-standing technology transfer agreement with NTP Radioisotopes in South Africa.

The company operates a B2B enterprise sales motion with three revenue streams: radioisotope supply (Lutetium-177 n.c.a. and Actinium-225) sold to hospitals, pharmaceutical companies, and radiopharmacies; investigational radiopharmaceutical supply through clinical trials and expanded access programs targeting oncology centers and nuclear medicine departments; and radiolabeling technical services and equipment provision. Specialized sales channels—RadioisotopeOperations, RadiopharmaOperations, and TechnicalServices—route customer inquiries to the appropriate operational team. Marketing is driven by scientific engagement through major oncology and nuclear medicine conferences (ASCO, SNMMI, EANM, ENETS, ESMO, NANETS), peer-reviewed publications, and a registered healthcare-professional portal, with corporate communications amplified via LinkedIn and YouTube. Capital structure is anchored by a USD 262.5 million non-dilutive debt facility transferred from Blue Owl Managed Funds to Perceptive Advisors in June 2026, supporting pipeline advancement and commercial-scale manufacturing build-out ahead of ITM-11's anticipated regulatory and commercial milestones.

ITM-Radiopharma firmographics

Firmographics
Name
ITM-Radiopharma
Legal name
ITM Isotope Technologies Munich SE
Website
https://itm-radiopharma.com
Company type
Private
Founded year
2004
Operating status
Operating
Headcount range
501–1,000 employees
Short description
ITM Isotope Technologies Munich SE is a privately held radiopharmaceutical biotech company that develops and supplies targeted radiopharmaceutical therapeutics and diagnostics, combining proprietary Lutetium-177 and Actinium-225 radioisotopes with targeting molecules for hard-to-treat tumors in oncology and nuclear medicine.
Ownership category
akta.pro rank

ITM-Radiopharma industry classification

Industry
Product category
Radiopharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254), In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAD
Radioisotope Production (Reactor/Cyclotron/Gamma)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAF
Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAH
Radionuclide Supply Chain & Logistics (Shielding/Transport/Distribution)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAC
Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine

Keywords

  • Radiopharmaceutical therapeutics
  • Medical radioisotope production
  • Precision oncology pipeline
  • Targeted radionuclide therapy
  • Lutetium-177 supply

Where ITM-Radiopharma is headquartered

Location

Headquarters

HQ city
Garching Bei München
HQ country
Germany
HQ region
Europe

Offices4 records

Markets served

ITM-Radiopharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Infrastructure, Personnel, Marketing or Sales, Operations

Revenue model

  1. Radioisotope Supply: ITM supplies medical radioisotopes (Lutetium-177 n.c.a., Actinium-225) to hospitals, pharmaceutical companies, and radiopharmacies globally. This includes both research-grade and GMP-quality isotopes for diagnostic and therapeutic applications.
  2. Radiopharmaceutical Products: Proprietary radiopharmaceutical therapeutics and diagnostics in clinical development, targeting neuroendocrine tumors, prostate cancer, and glioblastoma. The company operates clinical trial programs and expanded access programs for investigational products.
  3. Technical Services and Equipment: Radiolabeling services and equipment provision for hospitals and radiopharmacies preparing radiopharmaceuticals for clinical use.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

ITM-Radiopharma product offering

Product offering

Core offering

ITM-Radiopharma develops and manufactures targeted radiopharmaceutical therapeutics and diagnostics for precision oncology, combining proprietary radioisotopes (non-carrier-added Lutetium-177 and Actinium-225) with targeting molecules to treat hard-to-treat tumors such as neuroendocrine tumors, prostate cancer, and glioblastoma. The company operates a vertically integrated model spanning radioisotope production at the FRM II research reactor, GMP-certified radiopharmaceutical manufacturing, and global clinical development, supplying both investigational drug products and medical radioisotopes to hospitals, nuclear medicine departments, and clinical trial sites.

Product overview

ITM Isotope Technologies Munich SE is a leading radiopharmaceutical biotech company that develops a new generation of radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors. The company's offering comprises a broad precision oncology pipeline combining high-quality radioisotopes (Lutetium-177, Actinium-225) with targeting molecules. Key therapeutic candidates include ITM-11 (¹⁷⁷Lu-edotreotide) for neuroendocrine tumors which completed Phase 3 COMPETE trial, ITM-31 for glioblastoma, and ITM-22 for prostate cancer. ITM operates from manufacturing facilities in Germany (Garching, Neufahrn) with a U.S. headquarters in Princeton, NJ, leveraging two decades of radiopharma expertise and established global supply networks.

Differentiator

Problem solved

Functional benefit

Products and services

  • ITM-11 (n.c.a. 177Lu-edotreotide) Proprietary targeted radiotherapeutic investigational agent combining non-carrier-added Lutetium-177 with edotreotide for treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs); supplied to clinical trial sites and Expanded Access Programs through Medical Affairs.
  • ITM-31 Investigational targeted radiotherapeutic candidate for glioblastoma developed as part of ITM's precision oncology pipeline.
  • ITM-22 (ITM-24d) Investigational targeted radiotherapeutic candidate for prostate cancer, part of ITM's precision oncology pipeline.
  • ITM-63 (Terbium-161 DOTA-LM3) Investigational somatostatin receptor antagonist radiolabeled with Terbium-161 for treatment of gastroenteropancreatic neuroendocrine tumors; Phase 0 study ongoing.
  • ITM-23 (161Tb-SibuDAB) Investigational PSMA ligand radiolabeled with Terbium-161 for targeted radionuclide therapy in metastatic prostate cancer; Phase Ia/b study ongoing.
  • Lutetium-177 (n.c.a.) Non-carrier-added Lutetium-177 medical radioisotope supplied globally by ITM for use as a key component in radiopharmaceutical therapeutics and diagnostics for precision oncology applications, sold to hospitals, radiopharmacies, and pharmaceutical companies.
  • Actinium-225 Alpha-emitting medical radioisotope supplied by ITM for targeted radionuclide therapy applications; ITM is developing production capabilities for global supply.
  • COMPETE Phase 3 Trial Phase 3 randomized controlled clinical trial (NCT03049189) evaluating 177Lu-edotreotide vs everolimus in patients with inoperable, progressive Grade 1 or Grade 2 gastroenteropancreatic neuroendocrine tumors, which met its primary PFS endpoint.
  • COMPOSE Phase 3 Trial Phase 3 clinical study evaluating 177Lu-edotreotide in patients with well-differentiated, aggressive Grade 2 or Grade 3, somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.
  • Radiolabeling Services and Equipment Radiolabeling services and equipment provision for hospitals and radiopharmacies preparing radiopharmaceuticals for clinical use, delivered through ITM's Technical Services team.

Quantifiable outcome

  • ITM-11 demonstrated clinically and statistically significant improvement in progression-free survival (23.9 vs 14.1 months) compared to everolimus in GEP-NET patients (p=0.022)
  • +3 more outcomes

Companies that use ITM-Radiopharma

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles3 records

ITM-Radiopharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

ITM-Radiopharma partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core.

  • Technical University of Munich (TUM)coreStrategic or Co-development PartnerLong-standing collaboration with Technical University of Munich's FRM II research reactor and Klinikum rechts der Isar for radioisotope production and clinical research. Prof. Wolfgang Weber, Director of Nuclear Medicine at TUM, serves as a key opinion leader and collaborator.
  • NTP Radioisotopes (South Africa)coreStrategic or Co-development PartnerTechnology transfer agreement concluded in 2012 with NTP Radioisotopes for reliable and sustainable supply of n.c.a. 177Lu from NTP's GMP-certified facility in Pretoria, South Africa. Supports global supply chain reliability.
  • ETH Zurich - PSI (Switzerland)coreStrategic or Co-development PartnerCollaboration with Center for Radiopharmaceutical Sciences ETHZ-PSI for development of novel radiopharmaceuticals including PSMA radioligands and terbium-based therapies. Prof. Roger Schibli and Prof. Cristina Müller serve as key research collaborators.
  • University Hospital BaselcoreStrategic or Co-development PartnerClinical research collaboration with Dr. Julia Fricke and Prof. Damian Wild for GEP-NET studies including ITM-63 (DOTA-LM3 terbium-161) and other SSTR-targeting programs. Award-winning research partnership recognized with EANT Marie Curie Award 2024.
  • International Centers for Precision Oncology (ICPO) FoundationcoreStrategic or Co-development PartnerITM supported the ICPO Forum for Theranostics in Precision Oncology, hosted at ITM's headquarters campus in Garching/Munich. Collaborative event bringing together key opinion leaders in precision oncology and theranostics.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

ITM-Radiopharma competitors and assessment

Company assessment

Direct peers

  • Lantheus Holdings: U.S. radiopharmaceutical-focused company with a portfolio spanning diagnostic imaging agents (e.g., Pylarify PSMA PET) and an emerging radiotherapeutic pipeline (including 177Lu-PSMA assets). Highly comparable in business model as a vertically integrated diagnostic + therapeutic radiopharma specialist.
  • Orano Med: Subsidiary of Orano developing lead-212-based alpha-emitter targeted radiotherapies for oncology. Comparable as a next-generation radionuclide therapy developer pursuing a parallel non-Lu-177 platform — directly relevant to ITM's Tb-161/Ac-225 strategy.
  • Telix Pharmaceuticals: Commercial-stage radiopharma company developing and commercializing diagnostic and therapeutic radiopharmaceuticals (Illuccix for PSMA imaging, TLX591 177Lu-rosopatamab for prostate cancer). Closely comparable precision-oncology radiopharma peer with overlapping Lu-177 PSMA and imaging agents.
  • Bracco Imaging: Privately held diagnostic imaging company with a growing radiopharmaceutical franchise (Blue Earth Diagnostics — Axumin, Posluma). Comparable as a global diagnostic radiopharma manufacturer and commercializer, with ambitions extending into therapeutics.
  • PharmaLogic: U.S.-based contract manufacturer and radiopharmacy network producing and distributing PET and SPECT agents, including emerging Lu-177 therapeutic capabilities. Comparable vertically integrated radiopharmacy/CDMO model serving overlapping hospital customers.
  • Curium Pharma: One of the world's largest radiopharmaceutical manufacturers, supplying diagnostic and therapeutic nuclear medicine products to hospitals globally. Directly comparable as a vertically integrated radiopharma manufacturer with overlapping isotope and finished-dose capabilities.

Broad incumbents

  • Novartis: Global pharma major with approved radioligand therapies Lutathera (177Lu-DOTATATE for GEP-NETs) and Pluvicto (177Lu-PSMA-617 for mCRPC), the dominant incumbents in the exact indications ITM-11 is targeting. Most relevant competitive benchmark for commercial trajectory and pricing dynamics.
  • Bayer: Major pharma with Xofigo (radium-223) in the radiopharmaceutical space and a growing pipeline of targeted radionuclide therapies (e.g., Nubeqa-AlphaMedix combinations). Broad incumbent in oncology with overlapping radioligand interests.

Others

  • GE HealthCare: Global medical imaging and life sciences company with a sizable radiopharma manufacturing and distribution business (including 68Ga, 177Lu and theranostic offerings post-MPH acquisition). Broad incumbent with comparable manufacturing footprint and customer base.

Emerging players

  • PanTera: Belgian startup spun out of SCK CEN focused on large-scale Actinium-225 production for alpha-emitting radiopharmaceuticals. Comparable emerging supplier addressing the same next-generation radionuclide bottleneck ITM is targeting with its Ac-225 program.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

ITM-Radiopharma social profiles

Digital presence

ITM-Radiopharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ITM-Radiopharma leadership team

Management profile

Number of profiles

Profiles7 records

ITM-Radiopharma subsidiaries and ownership

Company hierarchy

Subsidiaries6 records

ITM-Radiopharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ITM-Radiopharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ITM-Radiopharma

What does ITM-Radiopharma do?

ITM-Radiopharma develops and manufactures targeted radiopharmaceutical therapeutics and diagnostics for precision oncology, combining proprietary radioisotopes (non-carrier-added Lutetium-177 and Actinium-225) with targeting molecules to treat hard-to-treat tumors such as neuroendocrine tumors, prostate cancer, and glioblastoma. The company operates a vertically integrated model spanning radioisotope production at the FRM II research reactor, GMP-certified radiopharmaceutical manufacturing, and global clinical development, supplying both investigational drug products and medical radioisotopes to hospitals, nuclear medicine departments, and clinical trial sites.

Is ITM-Radiopharma a public or private company?

ITM-Radiopharma is a private company. It is classified as unknown and is currently operating.

When was ITM-Radiopharma founded?

ITM-Radiopharma was founded in 2004. It employs 501 to 1,000 people.

Where is ITM-Radiopharma based?

ITM-Radiopharma is headquartered in Garching Bei München, Germany, in the Europe region.

How does ITM-Radiopharma make money?

Three revenue lines are on record. Radioisotope Supply is the primary driver. The others are radiopharmaceutical Products and technical Services and Equipment.

Who are ITM-Radiopharma's main competitors?

Direct peers on record are Lantheus Holdings, Orano Med, Telix Pharmaceuticals, Bracco Imaging, PharmaLogic and Curium Pharma. Broad incumbents are Novartis and Bayer. GE HealthCare is listed as an others. PanTera is listed as an emerging player.

Does ITM-Radiopharma have an API?

No public API is recorded for ITM-Radiopharma.

What industry is ITM-Radiopharma in?

ITM-Radiopharma's product category is Radiopharmaceuticals. Its primary akta.pro industry code is HLAIAGAB, Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy), with a secondary code of HLAIAGAD, Radioisotope Production (Reactor/Cyclotron/Gamma). Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals